SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.190+5.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: HardToFind who wrote (10183)5/7/2018 7:20:58 PM
From: HardToFind  Read Replies (1) of 12873
 
I'd ask what was wrong with the first valuation, but I already have about five ideas:
  1. Ms. Myers was not informed that NNVC had already paid for nine (9) drug indications that have gone nowhere so far, including the other herpes viruses using the same molecule.
  2. NNVC has already paid TheraCour for all of the research that went into this additional indication, plus a 30% markup.
  3. We don't know if, or for how much, we can produce this drug in commercial quantities.
  4. The company is running out of money, and cannot afford to license another indication prior to another equity raise. (Debt financing is out of the question because there is no income and in case of bankruptcy the meaningful assets fall to TC.)
  5. A 15% royalty on revenues would sink the company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News